The cardiovascular complications were highly prevalent in type 2 diabetes mellitus (T2DM), even at the early stage of T2DM or the state of intensive glycemic control. Therefore, there is an urgent need for the intervention of cardiovascular complications in T2DM. Herein, the new hybrids of NO donor and SGLT2 inhibitor were design to achieve dual effects of anti-hyperglycemic and anti-thrombosis. As expected, the preferred hybrid 2 exhibited moderate SGLT2 inhibitory effects and anti-platelet aggregation activities, and its anti-platelet effect mediated by NO was also confirmed in the presence of NO scavenger. Moreover, compound 2 revealed significantly hypoglycemic effects and excretion of urinary glucose during an oral glucose tolerance test in mice. Potent and multifunctional hybrid, such as compound 2, is expected as a potential candidate for the intervention of cardiovascular complications in T2DM.

心血管并发症在2型糖尿病（T2DM）中非常普遍，甚至在T2DM的早期阶段或强化血糖控制状态下也是如此。因此，迫切需要在T2DM中干预心血管并发症。本文中，设计了NO供体和SGLT2抑制剂的新杂种以获得抗高血糖和抗血栓形成的双重作用。如所预期的，优选的杂种2表现出中等的SGLT2抑制作用和抗血小板聚集活性，并且在NO清除剂的存在下也证实了其由NO介导的抗血小板作用。此外，化合物2在小鼠的口服葡萄糖耐量试验中发现了显着的降血糖作用和尿葡萄糖排泄。潜在的多功能复合物（例如化合物2）有望作为干预T2DM中心血管并发症的潜在候选药物。